News in Brief
Pharmacology - Dec 6
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
wire - news in brief
Category
Results 351 - 379 of 379.
Grassland Researchers Meet in Zurich
Switzerland is a grassland. The climate and soil provide ideal conditions for grass production, and thus for sustainable milk and meat production, whilst natural conditions are often unfavourable for arable farming. However, grass production too is facing new challenges. Despite extreme weather such as drought, the agricultural sector aims to produce top-quality forage, so that concentrate use can be reduced as much as possible.
Switzerland is a grassland. The climate and soil provide ideal conditions for grass production, and thus for sustainable milk and meat production, whilst natural conditions are often unfavourable for arable farming. However, grass production too is facing new challenges. Despite extreme weather such as drought, the agricultural sector aims to produce top-quality forage, so that concentrate use can be reduced as much as possible.
Sports scientists from the University of Basel found that providing telephone-based coaching over the phone is an effective method for getting people in Switzerland to adopt a physically active lifestyle. Physical activity is a good way to minimize various health risks - regardless of gender, age and fitness level.
Components for ESA rockets are illuminated with neutrons Rockets from the European Space Agency ESA fly into space with support from the Paul Scherrer Institute PSI. Imaging carried out at PSI in cooperation with Dassault Aviation ensures the quality of certain components of the Ariane 5 and Vega launch vehicles.
The Latin version of Théodore de Bry's Voyages is available on line in its entirety for the first time.
Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph
EPFL's Laboratory for Ultrafast Microscopy and Electron Scattering has received a grant from Google to use shaped electron beams in the cutting-edge field of Nuclear Excitation by Electron Capture (NEEC). Dr Fabrizio Carbone's Laboratory for Ultrafast Microscopy and Electron Scattering (LUMES) today announced that Google has funded a 4-year research project in the lab.
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Survey shows high levels of employee satisfaction at the University of Bern
On the whole, employees at the University of Bern are very satisfied or mostly satisfied with their work and, in general, have a high level of commitment. This is according to the results of the 2019 staff survey. One aspect which staff particularly enjoy is the diverse nature of their work. An up-to-date analysis of wage equality also yielded positive results: at the University of Bern, men and woman earn the same amount for work which is of equal value.
On the whole, employees at the University of Bern are very satisfied or mostly satisfied with their work and, in general, have a high level of commitment. This is according to the results of the 2019 staff survey. One aspect which staff particularly enjoy is the diverse nature of their work. An up-to-date analysis of wage equality also yielded positive results: at the University of Bern, men and woman earn the same amount for work which is of equal value.
The Fabula team at Twitter UK office. Left to right: Michael Bronstein, Fabrizio Frasca, Emanuele Rossi, Davide Eynard, Federico Monti, Damon Mannion (image: Stacey Conti).
Novartis Cosentyx first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
Cosentyx provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
In its first two years, the BRIDGE funding programme has financed 81 projects at the interface of basic science and science-based innovation.
FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
News in Brief
Pharmacology - Dec 6
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy